Abstract: It is an object of the present invention to provide a sensor, which is capable of measuring, quickly and in high accuracy, concentration of neutral fat from a sample such as a biological sample or the like, without executing pretreatment of the sample. This object is attained by a biosensor for measuring concentration of neutral fat, based on value of current flowing in the electrode system, having: an insulating substrate; an electrode system having a working electrode and a counter electrode, formed onto the insulating substrate: and a reaction layer having a lipoprotein lipase, a glycerol dehydrogenase and an electron mediator, formed at the upper part or the vicinity of the electrode system.

Abstract: It is an object of the present invention to provide a sensor, which is capable of measuring, quickly and in high accuracy, concentration of neutral fat from a sample such as a biological sample or the like, without executing pretreatment of the sample. This object is attained by a biosensor for measuring concentration of neutral fat, based on value of current flowing in the electrode system, having: an insulating substrate; an electrode system having a working electrode and a counter electrode, formed onto the insulating substrate: and a reaction layer having a lipoprotein lipase, a glycerol dehydrogenase and an electron mediator, formed at the upper part or the vicinity of the electrode system.

Abstract: A biosensor, comprising an insulating base plate, an electrode system containing at least a working electrode and a counter electrode and formed on the insulating base plate, and a sample-supplying section formed on the electrode system, wherein the sample-supplying section has a reaction layer comprising: a first reaction layer formed on the electrode system and containing at least a redox enzyme into which pyrroloquinoline quinone (PQQ), flavin adenine dinucleotide (FAD), or flavin mononucleotide (FMN) is incorporated as a prosthetic group; and a second reaction layer formed by applying, onto the first reaction layer, a solution including a lipid decomposing enzyme.

Abstract: The present invention is directed to an agent for inhibiting peritoneal membrane thickening which enables inhibition/prevention or treatment of the peritoneal membrane thickening and which mitigates adverse effect, and a dialysis fluid comprising the aforementioned thickening inhibitory agent.

Abstract: To provide a biosensor capable of measuring the concentration of specific component, such as glucose or neutral fat, in sample in a short time. The biosensor is A biosensor, comprising an insulating base plate, an electrode system containing at least a working electrode and a counter electrode and formed on the insulating base plate, and a sample-supplying section formed on the electrode system, wherein the sample-supplying section has a reaction layer comprising: a first reaction layer formed on the electrode system and containing at least a redox enzyme into which pyrroloquinoline quinone (PQQ), flavin adenine dinucleotide (FAD), or flavin mononucleotide (FMN) is incorporated as a prosthetic group; and a second reaction layer formed by applying, onto the first reaction layer, a solution including a lipid decomposing enzyme.

Abstract: PROBLEM The present invention is directed to provide a thickening inhibitory agent for inhibiting peritoneal membrane thickening which enables inhibition/prevention or treatment of the peritoneal membrane thickening and which mitigates adverse effect, and a dialysis fluid comprising the aforementioned thickening inhibitory agent.

Abstract: It is an object of the present invention to provide a sensor, which is capable of measuring, quickly and in high accuracy, concentration of neutral fat from a sample such as a biological sample or the like, without executing pretreatment of the sample. This object is attained by a biosensor for measuring concentration of neutral fat, based on value of current flowing in the electrode system, having: an insulating substrate; an electrode system having a working electrode and a counter electrode, formed onto the insulating substrate; and a reaction layer having a lipoprotein lipase, a glycerol dehydrogenase and an electron mediator, formed at the upper part or the vicinity of the electrode system.

Abstract: An ameliorating agent for cancer chemotherapy is disclosed, which comprises a chromanol glycoside represented by the following general formula (1) (wherein R1, R2, R3, and R4, which are identical or different from each other, stand for a hydrogen atom or a lower alkyl group, R5 stands for a hydrogen atom, a lower alkyl group, or a lower acyl group, X stands for a monosaccharide residue or an oligosaccharide residue optionally having the hydrogen atom of the hydroxyl group in the saccharide residue substituted with a lower alkyl group or a lower acyl group, n is an integer in the range of 0-6, and m is an integer in the range of 1-6). According to this invention, a novel ameliorating agent for cancer chemotherapy is provided which acts safely and effectively in a small dosage to enhance the carcinostatic action of an anti-cancer agent in cancer chemotherapy and repressing side effects by cancer chemotherapy as well.

Abstract: An ameliorating agent for cancer chemotherapy is disclosed, which comprises a chromanol glucoside represented by the following general formula (1) (wherein R1, R2, R3, and R4, which are identical or different from each other, stand for a hydrogen atom or a lower alkyl group, R5 stands for a hydrogen atom, a lower alkyl group, or a lower acyl group, X stands for a monosaccharide residue or an oligosaccharide residue optionally having the hydrogen atom of the hydroxyl group in the saccharide residue substituted with a lower alkyl group or a lower acyl group, n is an integer in the range of 0-6, and m is an integer in the range of 1-6). According to this invention, a novel ameliorating agent for cancer chemotherapy is provided which acts safely and effectively in a small dosage to enhance the carcinostatic action of an anti-cancer agent in cancer chemotherapy and repressing side effects by cancer chemotherapy as well.

Abstract: An dermatological agent for external use is disclosed which contains a chromanol glycoside represented by the following general formula (1) (wherein R1, R2, R3, and R4 which may be the same or different, each represent a hydrogen atom or a lower alkyl group, R5 represents a hydrogen atom, a lower alkyl group, or a lower acyl group, X represents a monosaccharic residue or an oligosaccharic residue optionally having the hydrogen atom of the hydroxyl group in the saccharic residue substituted with a lower alkyl group or a lower acyl group, n represents an integer in the range of 0-6, and m represents an integer in the range of 1-6). This is a novel dermatological agent for external use which excels in stability and percutaneous absorbency, manifests an effective action safely at a small application rate, and effectively prevents and cures the dermopathy.

Abstract: An agent for preventing and curing the hindrance of ischemic reperfusiton is disclosed which has as an active component thereof a chromanol glycoside represented by the following general formula: [wherein R1, R2, R3, and R4 independently denote a hydrogen atom or a lower alkyl group, R5 denotes a hydrogen atom, a lower alkyl group, or a lower acyl group, X denotes a monosaccharide residue or an oligosaccharide residue which may have a lower alkyl group or a lower acyl group substituted for the hydrogen atom of the hydroxyl group of the saccharide residue, n denotes an integer of 0-6, and m denotes an integer of 1-6]. The agent, even in a small dosage, acts safely and effectively on the affected part and allows the hindrances of ischemic reperfusion induced in heart, stomach, small intestine, liver, spleen, kidney, brain, and skin, and the hindrance induced during the transplantation of an internal organ to be prevented and cured.

Abstract: An agent for preventing and curing the hindrance of ischemic reperfusiton is disclosed which has as an active component thereof a chromanol glycoside represented by the following general formula: 1

Abstract: A preventive and curative agent for inflammatory bowel diseases is disclosed which has as an active ingredient thereof a chromanol glucoside represented by the following general formula (1) (wherein R1, R2, R3, and R4 represent identically or differently either a hydrogen atom or a lower alkyl group, R5 represents a hydrogen atom, a lower alkyl group, or a lower acyl group, X represents a monosaccharide residue or an oligosaccharide residue having the hydrogen atom in the hydroxyl group thereof optionally substituted with a lower alkyl group or a lower acyl group, n represents an integer of 0-6, and m represents an integer of 1-6). Owing to the use, as an active ingredient, of the chromanol glucoside excelling in water solubility and possessing an oxidization resisting action and a free radical resisting action, the agent can conspicuously repress the lesion of an inflammatory bowel disease and prominently ameriolate the condition of disease.

Abstract: This invention provides a novel chromanol glycoside which is a water soluble antioxidant excellent in heat and pH stability and production method thereof. It is a chromanol glycoside represented by the general formula (1): ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 independently are a hydrogen atom or a lower alkyl group, R.sup.5 is a hydrogen atom, a lower alkyl group, or a lower acyl group, X is a monosaccharide residue or an oligosacoharide residue, providing the hydrogen atom of the hydroxyl group of saccharide residue may be substituted by a lower alkyl group or a lower acyl group, n is an integer in the range of 0 to 4, and m is an integer in the range of 1 to 6.

Abstract: An N-acylamino acid compound represented by the general formula (1):R--CO--(NH--X--CO).sub.n --OR.sup.1 (1)wherein (NH--X--CO) is an amino acid residue, X in (NX--X--CO) is variable with the kind of amino acid to be used, R--CO is a saturated or an unsaturated fatty acid residue having 6 to 24 carbon atoms, R.sup.1 is hydrogen atom, sodium atom, potassium atom, or methyl group and n is an integer in the range of from 1 to 3, indicating that at least one histidine is contained as a component amino acid is disclosed, which is obtained by causing an N-hydroxysuccinimide ester to react with an amino acid or a peptide.The compound excels in antioxidizing power, emulsifying power, antibacterial power, chelating power, infrared absorbing power, and humidity-retaining power.

Abstract: This invention provides a novel chromanol glycoside which is a water soluble antioxidant excellent in heat and pH stability and production method thereof. It is a chromanol glycoside represented by the general formula (1): ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 independently are a hydrogen atom or a lower alkyl group, R.sup.5 is a hydrogen atom, a lower alkyl group, or a lower acyl group, X is a monosaccharide residue or an oligosaccharide residue, providing the hydrogen atom of the hydroxyl group of saccharide residue may be substituted by a lower alkyl group or a lower acyl group, n is an integer in the range of 0 to 4, and m is an integer in the range of 1 to 6.